BJC reports最新文献_第3页

Case report of three patients with end-stage recurrent glioblastoma treated with meldonium. 米屈肼治疗晚期复发性胶质母细胞瘤3例报告。

BJC reports Pub Date : 2025-04-28 DOI: 10.1038/s44276-025-00124-7

Sandra Bien-Möller, Martin E Weidemeier, Josefine Radke, Jörg Baldauf, Stefan Engeli, Mladen V Tzvetkov, Henry W S Schroeder

{"title":"Case report of three patients with end-stage recurrent glioblastoma treated with meldonium.","authors":"Sandra Bien-Möller, Martin E Weidemeier, Josefine Radke, Jörg Baldauf, Stefan Engeli, Mladen V Tzvetkov, Henry W S Schroeder","doi":"10.1038/s44276-025-00124-7","DOIUrl":"https://doi.org/10.1038/s44276-025-00124-7","url":null,"abstract":"Background: Glioblastoma is the most aggressive primary brain tumor in adults. The prognosis is still very poor with a median survival time less than a year. A growing body of data supports the role for fatty acid oxidation (FAO) in the aggressive behavior of glioblastoma. We have previously shown that meldonium, an orally active compound that impairs FAO, caused significant growth reduction of glioblastoma in mice. Here, we report three cases of experimental meldonium-containing therapy in end-stage recurrent glioblastoma patients.Methods: Three end-stage glioblastoma patients, who had second relapse tumor progression after standard of care therapy, received 500 mg meldonium twice a day on the top of the existing therapy regimen. Tolerability and treatment outcomes were monitored.Results: Meldonium was well tolerated by all three patients. One patient experienced long-term growth arrest and maintained clinically stable disease status, currently 24 months into treatment with meldonium. In contrast, the other two patients passed away.Conclusions: The case reports presented here suggest good tolerability and the potential for meldonium to improve outcome in glioblastoma patients. Controlled clinical trials need to follow to evaluate systematically possible benefits from the integration of meldonium into standard glioblastoma treatment protocols.","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"29"},"PeriodicalIF":0.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer risk according to lifestyle risk score trajectories: a population-based cohort study. 基于生活方式风险评分轨迹的癌症风险：一项基于人群的队列研究

BJC reports Pub Date : 2025-04-25 DOI: 10.1038/s44276-025-00141-6

Thi Minh Thu Khong, Thi Tra Bui, Hee-Yeon Kang, Eunjung Park, Moran Ki, Yoon-Jung Choi, Byungmi Kim, Jin-Kyoung Oh

{"title":"Cancer risk according to lifestyle risk score trajectories: a population-based cohort study.","authors":"Thi Minh Thu Khong, Thi Tra Bui, Hee-Yeon Kang, Eunjung Park, Moran Ki, Yoon-Jung Choi, Byungmi Kim, Jin-Kyoung Oh","doi":"10.1038/s44276-025-00141-6","DOIUrl":"https://doi.org/10.1038/s44276-025-00141-6","url":null,"abstract":"Background: While individual lifestyle behaviors have been associated with cancer risk, combined impact of these factors remains understudied. This research explores relationships between lifestyle risk score trajectories and cancer risk within the Korean population.Methods: A cohort of 3,451,189 cancer-free men and women who participated in a health examination between 2002 and 2003, provided by the National Health Insurance, was studied. Lifestyle risk score trajectories were determined using group-based trajectory modeling based on total score of four modifiable unhealthy behaviors: current smoking, heavy alcohol drinking, excess body weight, and physical inactivity repeatedly observed three times between 2002 and 2007. Scores ranged between 0 (low risk) and 8 (high risk). The Cox proportional hazards model was applied to examine the association between these trajectories and cancer incidence.Results: During the follow-up time (2008-2019), 312,075 cancer cases were identified. Among men, seven trajectories were identified, and trajectories of high lifestyle risk scores increased cancer risk of all cancer combined, cancer subgroupings, upper aero-digestive, stomach, colorectal, liver, gallbladder, pancreatic, lung, and bladder cancer, but inverse relation was observed for prostate cancer. Among women, four trajectory groups showed similar trends.Conclusions: Maintaining a healthy lifestyle and avoiding unhealthy behaviors are essential for cancer prevention.","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"28"},"PeriodicalIF":0.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12032105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic reprogramming in glioblastoma: a rare case of recurrence to scalp metastasis. 胶质母细胞瘤的代谢重编程：复发至头皮转移的罕见病例。

BJC reports Pub Date : 2025-04-24 DOI: 10.1038/s44276-025-00134-5

Amir Barzegar Behrooz, Hamid Latifi-Navid, Narges Zolfaghari, Somayeh Piroozmand, Ahmad Pour-Rashidi, Mahsa Bourbour, Fatemeh Jusheghani, Mahmoud Aghaei, Negar Azarpira, Fatemeh Mollasalehi, Sedigheh Alamdar, Ahmad Nasimian, Jabar Lotfi, Shahla Shojaei, Elham Nazar, Saeid Ghavami

{"title":"Metabolic reprogramming in glioblastoma: a rare case of recurrence to scalp metastasis.","authors":"Amir Barzegar Behrooz, Hamid Latifi-Navid, Narges Zolfaghari, Somayeh Piroozmand, Ahmad Pour-Rashidi, Mahsa Bourbour, Fatemeh Jusheghani, Mahmoud Aghaei, Negar Azarpira, Fatemeh Mollasalehi, Sedigheh Alamdar, Ahmad Nasimian, Jabar Lotfi, Shahla Shojaei, Elham Nazar, Saeid Ghavami","doi":"10.1038/s44276-025-00134-5","DOIUrl":"https://doi.org/10.1038/s44276-025-00134-5","url":null,"abstract":"Background: Glioblastoma (GB), an aggressive brain malignancy with a poor prognosis of 1.5-2 years, rarely exhibits extracranial metastasis (ECM). However, metabolic reprogramming has emerged as a key driver of GB progression and invasiveness. This study presents a rare case of recurrent GB with scalp metastasis, exploring how metabolic shifts enable GB cells to evade treatment and adapt to hostile environments, offering insights for developing innovative therapies.Methods: Tandem mass spectrometry (MS/MS) was employed to analyze amino acid profiles in both the recurrent and metastatic stages of GB. Systems biology approaches were used to uncover genetic alterations and metabolic reprogramming associated with the progression from recurrence to metastasis.Results: Our analysis revealed distinct amino acid utilization patterns in a patient with a molecular phenotype of wild-type IDH-1&2, TERT mutation, non-mutated BRAF and EGFR, and non-methylated MGMT. During recurrence and metastasis, significant differences in amino acid profiles were observed between blood and cerebrospinal fluid (CSF) samples. Additionally, protein-protein interaction (PPI) analysis identified key genomic drivers potentially responsible for the transition from recurrent to metastatic GB.Conclusions: Beyond established risk factors such as craniotomy, biopsies, ventricular shunting, and radiation therapy, our findings suggest that metabolic reprogramming plays a crucial role in the transition from recurrent to metastatic GB. Targeting these metabolic shifts could provide new avenues for managing and preventing extracranial metastasis in GB, making this an important focus for future research.","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"27"},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12022025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monitoring circulating tumor DNA by recurrent hotspot mutations in bladder cancer. 膀胱癌复发热点突变监测循环肿瘤DNA。

BJC reports Pub Date : 2025-04-24 DOI: 10.1038/s44276-025-00143-4

Shigehiro Tsukahara, Masaki Shiota, Takashi Matsumoto, Dai Takamatsu, Shohei Nagakawa, Nozomi Noda, Shinya Matsumoto, Mikako Yagi, Takeshi Uchiumi, Yuya Kunisaki, Dongchon Kang, Masatoshi Eto

{"title":"Monitoring circulating tumor DNA by recurrent hotspot mutations in bladder cancer.","authors":"Shigehiro Tsukahara, Masaki Shiota, Takashi Matsumoto, Dai Takamatsu, Shohei Nagakawa, Nozomi Noda, Shinya Matsumoto, Mikako Yagi, Takeshi Uchiumi, Yuya Kunisaki, Dongchon Kang, Masatoshi Eto","doi":"10.1038/s44276-025-00143-4","DOIUrl":"https://doi.org/10.1038/s44276-025-00143-4","url":null,"abstract":"Background: Liquid biopsy can evaluate minimally residual disease. Hotspot mutations are also common in non-coding regions among the MIBC patients. We evaluated the status of MIBC with hotspot mutations with cfDNA.Methods: Tumor and blood from MIBC patients were collected prospectively. We evaluate the VAF of mutations (TERT, PLEKHS1, ADGRG6 and WDR74) with digital PCR in tumor and cfDNA as somatic mutation. We originally designed and validated primers and probes. VAF of cfDNA and clinical imaging were matched. This study was approved by the Institutional Review Board (#2022-157).Result: 37 MIBC patients were enrolled and 28 (76%) patients had any hotspot. Among the 21 patients of follow-up cohort, cfDNA predicted recurrence 58 days earlier than the diagnosis by CT scan. Furthermore, the detection of ctDNA at the first visit after radical cystectomy was associated with recurrence free survival (P = 0.0043) and overall survival (P = 0.017). The patient who received neoadjuvant chemotherapy (NAC) and diagnosed as ypT0 belonged to the nonrecurrence group with negative ctDNA.Conclusion: Hotspot mutation is promising biomarker to predict earlier recurrence than CT-scan. Multiple detection of mutations in cfDNA contributes to reliable recurrence prediction.","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"26"},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12022302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the effect of differing centre hydration and anti-emetic policies on acute gastrointestinal and renal toxicities in the De-ESCALaTE trial. 在De-ESCALaTE试验中探讨不同中心水化和止吐策略对急性胃肠道和肾脏毒性的影响。

BJC reports Pub Date : 2025-04-23 DOI: 10.1038/s44276-025-00132-7

Anthony Kong, Matthew Hazell, Gulnaz Iqbal, Janet Dunn, Hisham Mehanna

{"title":"Exploring the effect of differing centre hydration and anti-emetic policies on acute gastrointestinal and renal toxicities in the De-ESCALaTE trial.","authors":"Anthony Kong, Matthew Hazell, Gulnaz Iqbal, Janet Dunn, Hisham Mehanna","doi":"10.1038/s44276-025-00132-7","DOIUrl":"https://doi.org/10.1038/s44276-025-00132-7","url":null,"abstract":"Background: The De-ESCALaTE trial confirmed the superiority of cisplatin over cetuximab in combination with radiotherapy for the treatment of low risk HPV+ oropharyngeal cancer (HPV + OPC). However, there were concerns about certain toxicities with the use of cisplatin, in particular nausea, vomiting, dehydration and renal toxicities.Methods: The De-ESCALaTE trial collected data on several centre level policies on hydration and anti-emetic use. Univariable and backwards stepwise multivariable logistic regression models were used to model the association between centre level policy variables and severe adverse events (SAEs) of interest and severe (grade 3-5) acute toxicities of interest. In addition, the predictive performance of each model was assessed.Results: Centre level policies including the use of a triple anti-emetics regimen pre and post chemotherapy, increased volumes of IV fluids given before and during cisplatin chemotherapy as well as oral fluids advised post chemotherapy, were all associated with a reduced odds of SAEs of interest. Only a policy to give diuretics was associated with a reduction of severe (grade 3-5) acute toxicities of interest.Conclusions: For centres with HPV + OPC patients undergoing chemoradiation, we recommend the use of specific hydration and anti-emetic policies to reduce the rates of relevant SAEs and severe acute toxicities.","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"25"},"PeriodicalIF":0.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Younger-onset type 2 diabetes associated with increased long-term cancer risk in Chinese adults: A 30-year follow-up of the Da Qing Diabetes Study. 中国成人年轻发病2型糖尿病与长期癌症风险增加相关：大庆糖尿病研究的30年随访

BJC reports Pub Date : 2025-04-22 DOI: 10.1038/s44276-025-00142-5

Siyao He, Xin Qian, Jinping Wang, Xiaoxia Shen, Yali An, Bo Zhang, Bo Chen, Hui Li, Xiaoping Chen, Yanyan Chen, Yang Wang, Chenggang Jin, Qiuhong Gong, Guangwei Li

{"title":"Younger-onset type 2 diabetes associated with increased long-term cancer risk in Chinese adults: A 30-year follow-up of the Da Qing Diabetes Study.","authors":"Siyao He, Xin Qian, Jinping Wang, Xiaoxia Shen, Yali An, Bo Zhang, Bo Chen, Hui Li, Xiaoping Chen, Yanyan Chen, Yang Wang, Chenggang Jin, Qiuhong Gong, Guangwei Li","doi":"10.1038/s44276-025-00142-5","DOIUrl":"https://doi.org/10.1038/s44276-025-00142-5","url":null,"abstract":"Background: We investigated the association between younger-onset type 2 diabetes, duration of diabetes, and cancer risk based on data from the Da Qing Diabetes Prevention Outcome Study (DQDPOS).Methods: The analysis recruited 620 younger-onset (age≤50 years) and 649 older-onset (age>50 years) patients with type 2 diabetes, and 310 younger non-diabetes controls (age≤50 years). Multiple regression analysis was used to test the influence of younger-onset diabetes and duration of diabetes on the long-term risk of cancer.Results: The annual incidence of all cancer among the non-diabetes, younger-, and older-onset type 2 diabetes was significantly different (3.7, 5.5, and 4.0/1000 person-years, respectively). The standard Cox analysis revealed that the patients with younger-onset diabetes had a significantly higher risk of cancer than those with older-onset diabetes (hazard ratio [HR]:1.81; 95% confidence interval [CI]:1.20-2.73) and younger non-diabetic controls (HR:2.43; 95% CI:1.34-4.41) after adjustment for diabetes duration and other confounders. Stepwise general linear regression model analysis revealed that a longer diabetes-free time was associated with longer lifetime cancer-free years (partial R2 = 0.36, p < 0.001), in addition to the non-modifiable predictor duration of diabetes.Conclusions: Younger-onset type 2 diabetes was significantly associated with an increased risk of cancer beyond the influence of diabetes duration.","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"24"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12015435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Solid lipid nanoparticles in pancreatic cancer treatment. 固体脂质纳米颗粒在胰腺癌治疗中的应用。

BJC reports Pub Date : 2025-04-11 DOI: 10.1038/s44276-025-00130-9

Mia Dunn, Lewis Dymock, Clare Hoskins

{"title":"Solid lipid nanoparticles in pancreatic cancer treatment.","authors":"Mia Dunn, Lewis Dymock, Clare Hoskins","doi":"10.1038/s44276-025-00130-9","DOIUrl":"https://doi.org/10.1038/s44276-025-00130-9","url":null,"abstract":"Pancreatic cancer comes with one of the poorest prognoses of all cancers and as such it is crucial that new therapies are developed to improve on the current statistics. Currently, chemotherapy is the cornerstone of pancreatic cancer treatment with several drugs, and combinations of drugs being utilised for their anti-cancer effect. However, pancreatic cancer has a dense stroma around the tumour and intratumoral bacteria which result in drugs having difficulty penetrating the tumour or being metabolised by bacteria rendering them inactive. The utilisation of nanotechnology in chemotherapy for pancreatic cancer has been a huge area of focus for researchers worldwide with most of the focus being on lipid-based, inorganic and polymer-based nanoparticles. Solid lipid nanoparticles which have been studied since being first published in the 1990s, have been poorly researched for pancreatic cancer applications. Being composed of physiological lipids, solid lipid nanoparticles offer a greatly reduced risk of acute or chronic toxicities arising compared to inorganic or polymeric nanoparticles. They also possess the ability to improve on circulation time, permeability, and bioavailability of many first-line chemotherapeutics.","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"21"},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11992092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An aspirin a day keeps cancer at bay. 每天一片阿斯匹林可以预防癌症。

BJC reports Pub Date : 2025-04-11 DOI: 10.1038/s44276-025-00138-1

Mangesh A Thorat

引用次数: 0

Immune checkpoint inhibitor therapy is associated with a decreased risk of developing melanoma brain metastases. 免疫检查点抑制剂治疗与黑色素瘤脑转移风险降低相关。

BJC reports Pub Date : 2025-04-11 DOI: 10.1038/s44276-025-00137-2

Anna Fager, Matilda Samuelsson, Roger Olofsson Bagge, Aldina Pivodic, Sara Bjursten, Max Levin, Henrik Jespersen, Lars Ny

{"title":"Immune checkpoint inhibitor therapy is associated with a decreased risk of developing melanoma brain metastases.","authors":"Anna Fager, Matilda Samuelsson, Roger Olofsson Bagge, Aldina Pivodic, Sara Bjursten, Max Levin, Henrik Jespersen, Lars Ny","doi":"10.1038/s44276-025-00137-2","DOIUrl":"https://doi.org/10.1038/s44276-025-00137-2","url":null,"abstract":"Background: Despite recent advancements in metastatic melanoma treatment, the emergence of melanoma brain metastases (MBM) continues to pose a challenge. This study aimed to explore factors associated with MBM development.Methods: This retrospective study included patients diagnosed with advanced melanoma (unresectable stages III and IV [M1a-c]) between 2013 and 2019 at Sahlgrenska University Hospital, Gothenburg, Sweden. Differences in baseline and primary tumor characteristics, mutational status, biomarker levels, and first-line treatment between patients who developed MBM (BM+) and patients who did not develop MBM (BM-) were analyzed using univariable and multivariable Cox proportional hazard regression.Result: Of 395 patients, 91 subsequently developed MBM. Patients who received immune checkpoint inhibitors (ICI) as first-line treatment had a reduced risk of MBM development (p ≤ 0.001). None of the eleven patients who received CTLA-4 inhibitors as monotherapy or in combination with PD-1 inhibitors as first-line treatment developed brain metastases. Elevated plasma levels of S100B (p = 0.021) and higher metastatic stage (p = 0.047) were also associated with an increased risk of MBM development.Conclusion: ICI treatment is associated with a decreased risk of MBM development, suggesting a protective role. Elevated S100B levels and stage IV disease at advanced melanoma diagnosis might indicate an increased risk of MBM development.","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"22"},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11992042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increasing use of artificial intelligence in genomic medicine for cancer care- the promise and potential pitfalls. 人工智能在癌症治疗的基因组医学中越来越多的应用——前景和潜在的缺陷。

BJC reports Pub Date : 2025-04-01 DOI: 10.1038/s44276-025-00135-4

Olivia O'Connor, Terri P McVeigh

引用次数: 0